| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $7.19M | +238K | +71.8% | $30.17 | 570K | Feb 22, 2025 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | -$232K | -8.84K | -1.55% | $26.30 | 562K | Feb 22, 2025 | Direct | F2, F3 |
| transaction | PFE | Common Stock | Tax liability | -$5.55M | -213K | -37.87% | $26.08 | 349K | Feb 22, 2025 | Direct | F4, F5 |
| holding | PFE | Common Stock | 5.36K | Feb 22, 2025 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -238K | -100% | $0.00 | 0 | Feb 22, 2025 | Common Stock | 238K | $30.17 | Direct |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | Price is the closing price of Pfizer common stock on February 21, 2025. |
| F4 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F5 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |